{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010140","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.549403+00:00","generated_at":"2026-05-24T21:39:08.862118+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mira Pharmaceuticals develops topical Ketamir-2 for localized pain; preclinical study underway","bullets":["Topical Ketamir-2 designed for slow release, enabling targeted pain relief with minimal systemic exposure.","Preclinical study assessing efficacy of topical formulation against inflammatory pain is ongoing.","Phase 1 oral trial for Ketamir-2 continues; Phase 2a in diabetic neuropathy planned by year-end 2025.","First human efficacy data from Phase 2a expected in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010140","json":"https://secwatch.observer/filing/0001493152-25-010140.json","markdown":"https://secwatch.observer/filing/0001493152-25-010140.md","text":"https://secwatch.observer/filing/0001493152-25-010140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315225010140/0001493152-25-010140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315225010140/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:39:08.862118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}